Tuesday, December 27, 2016 9:06:44 AM
LONG-TERM GROWTH ESTIMATE OF ZYNGA INC. (NASDAQ:ZNGA) AT $22.5
Analysts are expecting Zynga Inc. (NASDAQ:ZNGA) to post EPS of $-0.03 for the quarter that settled on 2016-12-31.
LONG-TERM GROWTH APPROXIMATION IS SET AT $22.5 ON THE FIRM. This releases sales & earnings data for the looming 3-5 years. A quarter before, estimate was $22.5. 9 analysts that cover Zynga Inc. (NASDAQ:ZNGA) have given price calculations for the next year. When the implication of the LTG is realized, it can be understood that it can also have an impact on long-term progression.
Long-term growth expected figure is the mean growth number amongst market ANALYSTS WHICH STUDY THE CORPORATION. IT IS A DATA FACT COLLECTED BY THOMSON REUTERS TO PROVIDE THE TWELVE-MONTHLY COMPOUND GROWTH PERCENTAGE in the impending years. LTG is the anticipated compound average rate of growth a forecaster accepts. It is quantified as a percentage growth yearly and classically figured on EPS, and also Funds from Operations, both stated as crucial for a particular corporation.
As most experts don’t contribute the notions of the growth progression rates, the predictions amassed are assumed to comprise future as well as past achievements with one-year covered, and are equalled on a CAGR basis.
Yet, analyst predictions at times incline to be extremely mistaken, unmistakably over longer-term duration. These anticipations remain interesting/ appreciated as a pointer to market expectations.
Consensus spot from these specialists presently sits at $3.338. The lowest projection is set at $2.5 for next one-year even if the best target is at $5. On a 1-5 scale, Zynga Inc. has a rating of 2.4 comprised of the 9 ratings.
Zynga Inc. last reported EPS of $-0.03 on 2016-11-02 for the quarter closed on 2016-09-30. The surprise factor was -50% which was $-0.01 away from the expected figure. The entity can announce quarterly report on 2017-02-08.
Souce:
transcriptdaily.com/uncategorized/long-term-growth-estimate-of-zynga-inc-nasdaqznga-at-22-5/18268/
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM